Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

14 Sept 2010

Abstract excerpt

The establishment of the role of MET in human cancer has led to the development of small-molecule inhibitors, many of which are currently in clinical trials. Thus far, nothing is known about their therapeutic efficacy and the possible emergence of resistance to treatment, a problem that has been often observed with other receptor tyrosine kinase (RTK) inhibitors. To predict mechanisms of acquired resistance, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20841479
DOI: 10.1158/0008-5472.can-10-0436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase InhibitorsPMID 20841479Read ↗

Amplification of <i>MET</i> may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Semantic proximity Read ↗

The role of MET in chemotherapy resistanceSemantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Anticancer drug resistance: An update and perspective.Semantic proximity Read ↗

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Semantic proximity Read ↗

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cellsSemantic proximity Read ↗

[MET receptor inhibition: Hope against resistance to targeted therapies?]Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.